Beyond Lantus: Sanofi Signs Diabetes Deal With Wellstat
This article was originally published in The Pink Sheet Daily
Executive Summary
For a total deal value of $350 million, Sanofi gains global rights to Wellstat's Phase II first-in-class oral insulin sensitizer.